GSK’s two-drug HIV therapy shines in two big studies

Signage for GlaxoSmithKline is seen on it's offices in London, BritainGlaxoSmithKline's already fast-growing HIV drug business has received an important boost with the success of two major clinical studies testing a new two-drug treatment regimen to control the virus that causes AIDS. The approach is a departure from conventional triple drug cocktails that can cause troublesome side effects, especially among older patients who make up a growing proportion of those treated for the disease. Antiretroviral therapy has turned HIV from a death sentence into a manageable condition but patients need to stay on treatment for life, so there is a growing focus on making medication as well-tolerated as possible.



Sexual Health News Headlines – Yahoo! News